SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2001 / Cilt: 31 - Sayı: 6

Sublingual valsartan in hypertensive urgency

Yüksel GÖKEL
Nazan ALPARSLAN
Saime PAYDAŞ
Güven KUVANDIK
Pages
565–567
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Sublingual valsartan in hypertensive urgency

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sublingual valsartan in hypertensive urgency
📊
Key Findings & Data:Sublingual valsartan in hypertensive urgency
💡
Conclusion & Impact:Sublingual valsartan in hypertensive urgency
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Sublingual valsartan in hypertensive urgency

🔖

Cite This Article

GÖKEL, Y., ALPARSLAN, N., PAYDAŞ, S., KUVANDIK, G. (2022). Sublingual valsartan in hypertensive urgency. Turkish Journal of Medical Sciences, Cilt: 31 - Sayı: 6, 565–567. https://ajindex.com/articles/612334

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bales A. Hypertensive crisis: How to tell if it's an emergency or an urgency. Postgraduate Medicine 105: 119-130, 1999
  2. Gifford RW Jr. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV). Arch Intern Med 153: 154-183, 1993
  3. Marigliano V, Santilli D, Fiorani M, Ariani A, Cacciafesta M, Ferry C, Piccirillo G. Hypertensive emergencies in old age: effects of angiotensin converting enzyme inhibition. J Hypertens 6 (1): 91-93, 1998
  4. Angeli P, Chiesa M, Caregaro L, Merkel C, Sacerdoti D, Rondana M, Gatta A. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. Arch Intern Med 151: 678-682, 1991
  5. Kitiyakara C, Guzman NJ. Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 9(1): 133-142, 1998
  6. Grossman E, Ironi AN, Messerli FH. Comparative tolerability profile of hypertensive crisis treatments. Drug Saf 19 (2): 99-122, 1998
  7. Ceyhan B, Karaaslan Y, Caymaz O, Oto A, Oram E, Oram A, Ugurllu S. Comparison of sublingual captopril and sublingual nifedipine in hypertensive emergencies. Japan J Pharmacol 52: 189-193, 1990
  8. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose related increase in mortality in patients with coronary heart disease. Circulation 92 (5): 1926- 1931, 1995
  9. Siragy H. Angiotensin II receptor blockers: review of the binding characteristics. Am J Cardiol 84 (10): 3- 8, 1999
  10. Singh NK, Goyal RK. New classes of antihypertensive drugs: therapeutic potentials. Clin Exp Hypertens 21 (1-2): 137-143, 1999
  11. Williams GH. Hypertensive vascular disease. Harrison's principles of Internal Medicine (Eds. AS Fauci and E Braunwald) McGraw-Hill. New York 1998, pp: 1380-1394
  12. Mann SJ, Atlas SA: Hypertensive Emergencies. Hypertension, Pathophysiology, Diagnosis and Management (Eds. JH Laragh and BM Brenner) Raven Press. New York 1995, pp: 3009-3022
  13. Kaplan NM: Clinical Hypertension, Williams and Wilkins. Baltimore 1998, pp: 265-280
  14. Hirschl MM, Herkner H, Bur A, Woisetschlager C, Gamper G, Frossard M, Laggner AN. Course of blood pressure within the first 12 h of hypertensive urgencies. J Hypertens 16 (2): 251-255, 1998
  15. Gškel Y, Satar S, Paydaß S. A comparison of the effectiveness of sublingual losartan, sublingual captopril and sublingual nifedipine in hypertensive urgency. Tr J Med Sci 29: 655-660, 1999.